Clinical Decision-Making in Ulcerative Colitis: Considerations for Improved OutcomesPremiere Date: Monday, March 26, 2018
This activity offers CE credit for:%>
- Physicians (CME)
All other clinicians will receive a Certificate of Attendance stating this activity was certified for AMA PRA Category 1 Credit™
Credit Expiration Date:
Tuesday, March 26, 2019
Note: Credit Is No Longer Available
|David T. Rubin, MD, FACG, AGAF, FACP, FASGE, FRCP (Edinburgh)
Joseph B. Kirsner Professor of Medicine
Chief, Section of Gastroenterology, Hepatology and Nutrition
Director, Inflammatory Bowel Disease Center
University of Chicago Medicine
|William J. Sandborn, MD
Professor of Medicine and Adjunct Professor of Surgery
Chief, Division of Gastroenterology
Vice Chair for Clinical Operations, Department of Medicine
Director, UCSD IBD Center
University of California San Diego and UC San Diego Health System
La Jolla, CA
The goal of treatment of ulcerative colitis (UC) is achieving and sustaining remission. Variations in treatment patterns and care for moderate-to-severe UC are prevalent despite data demonstrating that early appropriate biologic therapy is more effective than conventional management of disease. The AGA has developed an evidence-based UC Care Pathway to guide treatment decisions for moderate- to high-risk patients; yet, in clinical practice, many clinicians are not integrating this pathway into their decision-making.
Join the CME Outfitters mobile case series designed to test your knowledge, confidence, and performance in optimizing treatment for patients with UC.
At the end of this CE activity, participants should be able to:
- Examine strategies to improve clinical decision-making in patients with ulcerative colitis.
Supported by an educational grant from Takeda Pharmaceuticals USA.
Gastroenterologists, physician assistants, nurse practitioners, nurses, and pharmacists who treat patients with Ulcerative Colitis.
CME Credit (Physicians):
Provided by the American Gastroenterological Association and CME Outfitters.
The American Gastroenterological Association (AGA) Institute is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The AGA Institute designates this enduring material for a maximum of .25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
CNE Credit (Nurses):
Provider approved by the California Board of Registered Nursing, Provider Number CEP 15510, for .25 contact hours
Note to Nurse Practitioners and Clinical Nurse Specialists: the content of this activity pertains to pharmacology. Earn up to .25 contact hours of pharmacotherapeutic contact hours.
Note to Nurse Practitioners: Nurse practitioners can apply for AMA PRA Category 1 CreditTM through the American Academy of Nurse Practitioners (AANP). AANP will accept AMA PRA Category 1 CreditTM from organizations accredited by the Accreditation Council for Continuing Medical Education. Nurse practitioners can also apply for credit through their state boards.
Note to Physician Assistants: AAPA accepts certificates of participation for educational activities certified for AMA PRA Category 1 CreditTM from organizations accredited by the Accreditation Council for Continuing Medical Education.
In accordance with the ACCME's Standards for Commercial Support of Continuing Medical Education, all faculty and planning partners must disclose any financial relationship(s) or other relationship(s) held within the past 12 months. The AGA Institute implements a mechanism to identify and resolve all conflicts of interest prior to delivering the educational activity to learners.
Dr Rubin reports that he receives grant support from AbbVie Inc.; Genetech, Inc./Roche; Janssen Pharmaceuticals, Inc.; Prometheus Laboratories Inc.; Shire; Takeda Pharmaceuticals U.S.A., Inc.; and UCB, Inc. He serves as a consultant for AbbVie Inc.; AbGenomics; Allergan; Amgen Inc.; Celgene Corporation; Forward Pharma; Genentech, Inc./Roche; Janssen Pharmaceuticals, Inc.; Merck & Co., Inc.; Miraca Life Sciences, Inc.; Napo Pharmaceuticals, Inc.; Pfizer Inc.; Salix Pharmaceuticals; Samsung Bioepis; Sandoz; Shire; Takeda Pharmaceuticals U.S.A., Inc.; and TARGET PharmaSolutions, Inc.
Dr. Sandborn reports that he receives grant support from AbbVie Inc.; Amgen Inc.; Celgene Corporation; Eli Lilly and Company; Genentech, Inc.; Gilead; Janssen Pharmaceuticals, Inc.; and Pfizer Inc. He is a consultant for AbbVie Inc.; Allergan; Amgen Inc.; Celgene Corporation; Eli Lilly and Company; Genentech, Inc.; Gilead; Janssen Pharmaceuticals, Inc.; Pfizer Inc.; Robarts Clinical Trials (owned by Western University, London, Ontario, CA); and UCB, Inc.
Kashemi Rorie, PhD (planning committee) has no disclosures to report.
Jan Perez (planning committee) has no disclosures to report.
Shari Tordoff (planning committee) has no disclosures to report.
Disclosures were obtained from the CME Outfitters, LLC staff: No disclosures to report.
Disclosures were obtained from the AGA Institute CME subcommittee: No disclosures to report. The members of the AGA Institute CME subcommittee are:
Sarah N. Flier, MD (chair)
Danielle K. Turgeon
Sandra M. Amos
Maura H. Davis
Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.
Questions about this activity? Call us at 877.CME.PROS (877.263.7767).